Kura Oncology Stock Analysis


USD 13.07  0.59  4.32%   

The big decline in price over the last few months for Kura Oncologymay raise some interest from investors. The stock closed today at a share price of 13.07 on 947,400 in trading volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in September. However, diversifying your holdings with Kura Oncology or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.62. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Kura Oncology partners.
Please see Correlation Analysis.
The Kura Oncology stock analysis report makes it easy to digest most publicly released information about Kura Oncology and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Kura Oncology Stock analysis module also helps to analyze the Kura Oncology price relationship with some important fundamental indicators such as market cap and management efficiency.

Kura Oncology Stock Analysis Notes

About 101.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kura Oncology recorded a loss per share of 1.69. The entity had not issued any dividends in recent years. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 117 people. To find out more about Kura Oncology contact Troy Wilson at 858 500 8800 or learn more at https://kuraoncology.com.

Kura Oncology Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kura Oncology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kura Oncology or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kura Oncology generated a negative expected return over the last 90 days
Kura Oncology has high historical volatility and very poor performance
Net Loss for the year was (132.22 M) with profit before overhead, payroll, taxes, and interest of 0.
Kura Oncology currently holds about 480.08 M in cash with (108.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.2.
Latest headline from www.marketscreener.com: KURA ONCOLOGY, INC. Change in Directors or Principal Officers - Marketscreener.com

Kura Oncology Upcoming and Recent Events

Earnings reports are used by Kura Oncology to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kura Oncology previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Kura Oncology SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kura Oncology prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kura Oncology investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kura Oncology specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
23rd of June 2022
Submission of Matters to a Vote of Security Holders
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
10th of March 2022
Unclassified Corporate Event
24th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition. Termination of a Material Definitive Agreement. Entry into a Material Definitive Agreement
11th of February 2022
Unclassified Corporate Event
3rd of February 2022
Unclassified Corporate Event
2nd of February 2022
Unclassified Corporate Event

Kura Oncology Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Kura Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kura Oncology backward and forwards among themselves. Kura Oncology's institutional investor refers to the entity that pools money to purchase Kura Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ecor1 Capital LlcCommon Shares6.6 M121.7 M
Blackrock IncCommon SharesM91 M
Avoro Capital Advisors LlcCommon Shares4.8 M88 M
Suvretta Capital Management LlcCommon SharesM73.6 M
Deep Track Capital LpCommon Shares3.7 M67.8 M
Vanguard Group IncCommon Shares3.3 M61.1 M
Holocene Advisors LpCommon Shares3.3 M59.7 M
Note, although Kura Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kura Oncology Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 885.86 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kura Oncology's market, we take the total number of its shares issued and multiply it by Kura Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (14.88) % which means that it has lost $14.88 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (24.9) %, meaning that it created substantial loss on money invested by shareholders. Kura Oncology management efficiency ratios could be used to measure how well kura oncology manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 4th of October, Kura Oncology secures the mean deviation of 2.74, and Risk Adjusted Performance of (0.14). Kura Oncology technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Kura Oncology, which can be compared to its peers in the industry. Please verify Kura Oncology variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Kura Oncology is priced some-what accurately, providing market reflects its recent price of 13.07 per share. Given that Kura Oncology has jensen alpha of (0.42), we recommend you to check Kura Oncology's last-minute market performance to make sure the company can sustain itself at a future point.

Kura Oncology Price Movement Analysis

The minimum time period for execution of this function requires larger time horizon. Please increase the time horizon for this function. The output start index for this execution was zero with a total number of output elements of zero. The Instantaneous Trendline is a moving-average-like indicator which is formed by removing the Dominant Cycle from Kura Oncology price series.

Kura Oncology Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kura Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kura Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kura Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Kura Oncology Predictive Daily Indicators

Kura Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kura Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Kura Oncology Forecast Models

Kura Oncology time-series forecasting models is one of many Kura Oncology's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kura Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Kura Oncology Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kura Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kura Oncology shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Kura Oncology. By using and applying Kura Oncology Stock analysis, traders can create a robust methodology for identifying Kura Oncology entry and exit points for their positions.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 117 people.

Current Kura Oncology Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kura Oncology analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kura Oncology analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
42.25Strong Buy4Odds
Kura Oncology current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Kura Oncology analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kura Oncology stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kura Oncology, talking to its executives and customers, or listening to Kura Oncology conference calls.
Kura Oncology Analyst Advice Details

Kura Oncology Stock Analysis Indicators

Kura Oncology stock analysis indicators help investors evaluate how Kura Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kura Oncology shares will generate the highest return on investment. By understating and applying Kura Oncology stock analysis, traders can identify Kura Oncology position entry and exit signals to maximize returns.
Quick Ratio27.08
Fifty Two Week Low10.41
Shares Short Prior Month4.85M
Average Daily Volume Last 10 Day1.08M
Average Daily Volume In Three Month844.52k
Shares Percent Shares Out7.97%
Short Percent Of Float8.13%
Forward Price Earnings-5.79
Float Shares41.79M
Fifty Two Week High19.93
Enterprise Value To Ebitda-4.12
Fifty Day Average14.78
Two Hundred Day Average14.74
Please see Correlation Analysis. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for analysis

When running Kura Oncology price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Global Correlations
Find global opportunities by holding instruments from different markets
CEO Directory
Screen CEOs from public companies around the world
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Kura Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.